In 2013, 503B Outsourcing Facilities came into existence as a result of the Drug Quality and Security Act (DQSA). The DQSA created Section 503B of the Federal Food, Drug, and Cosmetic Act, prompting extensive regulatory changes in the safe and effective compounding of drugs and medicines.
In addition, 503B compounders must provide non-sterile and sterile drug preparations expediently and cost-effectively because the provision of safe and of high-quality drugs are vital.
And that’s where the Nephron 503B Outsourcing Facility comes into play. This division of Nephron Pharmaceuticals supplies pre-filled syringes and sterile medications to alleviate drug shortage needs. In fact, the Nephron 503B Outsourcing Facility manufactures various products that are in short supply under Current Good Manufacturing Practice (cGMP) conditions.
Nephron Pharmaceuticals Corporation is a leading manufacturer of generic respiratory and 503B outsourcing medications. We produce affordable, high-quality inhalation solutions and suspension products that treat respiratory conditions, and we are the only manufacturer of Racemic Epinephrine, 2.25%, 0.5mL.
In addition to working as a CNA for the past 13 years, Lucie has broad experience in communications, editing, writing, public relations and research, both in the private sector and for non-profits. For the last several years, she has actively worked as a communications, marketing and PR consultant for numerous clients, most notably CVS Health, Towers Watson, Mars Inc, ReadyTech, Ancestry, Aartrijk, Wildflower Health, Communication Partners Inc, ExpertBeacon, Liberty Global, Acrobatiq and Words & Numbers.
This post is related to:
Admixture Compounding Services (503B Outsourcing Facilities)
